Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer

In advanced non-small cell lung cancer (NSCLC), response to immunotherapy is difficult to predict from pre-treatment information. Given the toxicity of immunotherapy and its financial burden on the healthcare system, we set out to identify patients for whom treatment is effective. To this end, we used mutational signatures from DNA mutations in pre-treatment tissue. Single base substitutions, doublet base substitutions, indels, and copy number alteration signatures were analysed in m = 101 patients (the discovery set). We found that tobacco smoking signature (SBS4) and thiopurine chemotherapy exposure-associated signature (SBS87) were linked to durable benefit. Combining both signatures in a machine learning model separated patients with a progression-free survival hazard ratio of ![Graphic][1] on the cross-validated discovery set and ![Graphic][2] on an independent external validation set ( m = 56). This paper demonstrates that the fingerprints of mutagenesis, codified through mutational signatures, select advanced NSCLC patients who may benefit from immunotherapy, thus potentially reducing unnecessary patient burden. ### Competing Interest Statement HCD: None to declare; BvE: None to declare; MT: None to declare; GAL: None to declare; ES: Honoraria/speakers fee: Bio-Rad, Roche, Agena Bioscience, Illumina, Lilly; Consulting or Advisory Role: MSD/Merck, Astellas, Bayer, BMS, Agena Bioscience, Janssen Cilag (Johnson \& Johnson), Novartis, Roche, AstraZeneca, Amgen, Lilly; Research Funding: Biocartis, Bio-Rad, Roche, Agena Bioscience, AstraZeneca, InVitae/Archer (all paid to UMCG); Travel, Accommodations, Expenses: Roche Molecular Diagnostics, Bio-Rad. LCLTvK: Grants, non-financial support from Roche, advisory board presence for AstraZeneca, Novartis, Merck, Janssen-Cilag, Bayer, BMS, nanoString and Pfizer, grants and non-financial support from Invitae, non-financial support from Biocartis, grants from Bayer, non-financial support from nanoString. TJNH: Advisory/consultancy fees from AstraZeneca, Bristol-Myers-Squibb, Merck Sharp Dohme, Roche, and research grants/funding from AstraZeneca, Hoffmann-La Roche. HJMG: Consulting or Advisory Role: Novartis, Lilly, Roche/Genentech. [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif